The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Randomized Phase III Clinical Trial of Daunoxome Versus Combination Chemotherapy With Adriamycin/Bleomycin/Vincristine (ABV) in the Treatment of HIV-Associated Kaposi's Sarcoma.
Official Title: A Randomized Phase III Clinical Trial of Daunoxome Versus Combination Chemotherapy With Adriamycin/Bleomycin/Vincristine (ABV) in the Treatment of HIV-Associated Kaposi's Sarcoma.
Study ID: NCT00002093
Brief Summary: To compare the toxicity profiles (severity and time to onset from initiation of therapy) between daunorubicin (liposomal) and combination chemotherapy with doxorubicin/bleomycin/vincristine (ABV), with both regimens administered in combination with antiretroviral therapy. To compare the duration of responses, response rates, and times to response.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Univ of Arizona / Arizona Cancer Ctr, Tucson, Arizona, United States
Kenneth Norris Jr Cancer Hosp, Los Angeles, California, United States
Desert Hosp Comprehensive Cancer Ctr, Palm Springs, California, United States
Saint Francis Mem Hosp, San Francisco, California, United States
Davies Med Ctr, San Francisco, California, United States
Denver Gen Hosp, Denver, Colorado, United States
George Washington Univ Med Ctr, Washington, District of Columbia, United States
Univ of Miami Dept of Medicine, Miami, Florida, United States
Northwestern Univ Med School, Chicago, Illinois, United States
New England Deaconess Hosp, Boston, Massachusetts, United States
New York Univ Med Ctr, New York, New York, United States
Kaiser Permanente Med Ctr, Portland, Oregon, United States
Dr Edward Stool, Houston, Texas, United States